Hepatitis C therapy—the future looks bright

[1]  P. Troke,et al.  968 GENOTYPIC CHARACTERISATION OF HCV NS5B FOLLOWING 8-DAY MONOTHERAPY WITH THE POLYMERASE INHIBITOR PF-00868554 IN HCV-INFECTED SUBJECTS , 2009 .

[2]  D. Hazuda,et al.  Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees , 2008, Antimicrobial Agents and Chemotherapy.

[3]  G. Everson,et al.  R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin , 2008, Hepatology.

[4]  A. Kosaka,et al.  Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. , 2008, The Journal of antimicrobial chemotherapy.

[5]  S. A. Qureshi.  Hepatitis C virus—biology, host evasion strategies, and promising new therapies on the horizon , 2007, Medicinal research reviews.

[6]  Charles M. Rice,et al.  Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry , 2007, Nature.

[7]  M. Silva,et al.  A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). , 2006, Journal of hepatology.

[8]  A. Kwong,et al.  Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease , 2006, Antimicrobial Agents and Chemotherapy.